Nuclear Medicine
Nuclear Medicine Specialist & Molecular Imaging Consultant10+ Years of Experience in Nuclear Medicine, Molecular Imaging, PET-CT/PET-MR and Theranostics.
HCG Cancer Hospital
Kolkata
Dr. Arunava Haldar is an experienced Nuclear Medicine Specialist and Molecular Imaging Consultant in Kolkata with expertise in diagnostic nuclear medicine, PET-CT, PET-MR imaging and theranostics. He currently practices as a Consultant in Nuclear Medicine at HCG Cancer Hospital, New Town, Kolkata.
He completed his MBBS from Maulana Azad Medical College, New Delhi, followed by a Diploma in Radiation Medicine from the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi. He subsequently completed his DNB in Nuclear Medicine from Apollo Hospitals, Chennai.
Dr. Arunava Haldar has extensive experience in oncological and non-oncological PET imaging. His clinical work includes PET-CT and PET-MR scans using advanced radiotracers for cancer detection, staging, treatment response assessment and disease monitoring. His expertise also includes cardiac PET imaging, brain PET imaging and nuclear bone scans.
His clinical interests extend to theranostics and targeted radionuclide therapy. He is experienced in radioiodine treatment for thyroid disorders and differentiated thyroid cancers, Lutetium-177 based therapies for neuroendocrine and prostate cancers, PSMA-targeted treatments and other advanced radionuclide therapies.
Dr. Haldar also has expertise in PET-CT-guided procedures, sentinel lymph node mapping and nuclear medicine-based management of metastatic bone pain. His combination of diagnostic molecular imaging and targeted radionuclide treatment allows him to contribute to personalised cancer evaluation and treatment planning.
PET-CT imaging combines metabolic and anatomical information to help identify, stage and monitor different cancers. Dr. Arunava Haldar has experience in oncological and non-oncological PET-CT imaging using appropriate radiotracers based on the patient's clinical condition.
PET-MR combines molecular PET imaging with detailed MRI information. It can be useful for evaluating selected cancers and neurological conditions while providing detailed soft-tissue assessment.
PSMA PET-CT is an advanced molecular imaging technique commonly used in the evaluation of prostate cancer. It can assist with staging, detection of recurrent disease and planning of PSMA-targeted radionuclide therapy.
DOTA PET-CT is particularly useful in evaluating neuroendocrine tumours. The scan helps determine the distribution of disease and whether a patient may be suitable for targeted radionuclide treatments such as PRRT.
Radioiodine therapy uses radioactive iodine to manage selected thyroid conditions. It may be used for hyperthyroidism as well as following treatment for differentiated thyroid cancer when clinically indicated.
High-dose radioactive iodine may be recommended for selected patients with differentiated thyroid cancer to destroy residual thyroid tissue or treat iodine-avid disease after surgery.
Lutetium-177 peptide receptor radionuclide therapy is a targeted treatment used for selected neuroendocrine tumours that demonstrate suitable receptor expression on molecular imaging.
Lutetium-177 PSMA therapy is a targeted radionuclide treatment used in appropriately selected patients with advanced prostate cancer whose disease demonstrates PSMA expression.
Actinium-225-based targeted alpha therapy is an advanced theranostic approach that may be considered for selected patients with neuroendocrine tumours or prostate cancer after specialist assessment.
Cardiac PET imaging provides information about myocardial blood flow, metabolism and viability and may assist cardiologists in the evaluation of selected cardiac conditions.
Brain PET imaging evaluates metabolic and molecular processes within the brain and may support assessment of selected neurological disorders and brain tumours.
A nuclear bone scan helps identify changes in bone metabolism and may be used to evaluate metastatic disease, unexplained bone pain, infection and other bone abnormalities.
PET-CT guidance can help identify metabolically active areas for selected image-guided interventions and biopsies, supporting accurate tissue sampling where clinically appropriate.
Nuclear medicine-based sentinel lymph node mapping can help identify the first lymph nodes likely to receive drainage from a tumour and may support surgical management of selected cancers.
Radionuclide therapy may be used for palliation of pain caused by selected bone metastases. Treatment is planned after assessing the patient's disease pattern and overall clinical condition.
MBBS, DRM (Diploma in Radiation Medicine), DNB (Nuclear Medicine)
PET-CT Imaging, PET-MR Imaging, Nuclear Medicine Imaging, Molecular Imaging, Cancer PET Scans
Genuine patient experiences and treatment feedback.
Quick answers to common questions about Dr. Arunava Haldar
Dr. Arunava Haldar specialises in Nuclear Medicine, with clinical interests in molecular imaging, PET-CT, PET-MR and theranostics.
Dr. Arunava Haldar holds an MBBS from Maulana Azad Medical College, a Diploma in Radiation Medicine from INMAS, New Delhi, and a DNB in Nuclear Medicine from Apollo Hospitals, Chennai.
Dr. Arunava Haldar has more than 10 years of experience in nuclear medicine, diagnostic imaging and theranostics.
Dr. Arunava Haldar currently practices at HCG Cancer Hospital, New Town, Kolkata.
Yes. His expertise includes oncological and functional PET-CT imaging, including FDG PET-CT, PSMA PET-CT, DOTA PET-CT and other specialised molecular imaging studies.
Contact us for personalized help or to schedule an appointment.